Protocol IM119-013: A Phase IIa randomised, double-blind, placebo controlled study to evaluate the clinical efficacy, safety and pharmacokinetics of three different doses of BMS 582949 given orally... (2008)
- Grant type:
- Bristol-Myers Squibb Pharmaceuticals Pty Limited
- Researchers:
-
-
- Funded by:
- Bristol-Myers Squibb Pharmaceuticals Pty Limited
